Design Therapeutics (DSGN) Profit After Tax (2020 - 2026)
Design Therapeutics (DSGN) reported Profit After Tax of -$17.6 million for Q1 2026, little changed on a YoY basis from -$17.6 million in Q1 2025, and down 10.25% sequentially from -$16.0 million in Q4 2025.
Design Therapeutics (DSGN) Profit After Tax (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Profit After Tax data on file, last reported at -$17.6 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax changed 0.45% year-over-year to -$17.6 million; the trailing twelve-month figure through Mar 2026 stood at -$69.7 million (down 24.05% YoY), and the FY2025 full-year result was -$69.8 million, down 40.74% from the prior year.
- Profit After Tax eased to -$17.6 million in Q1 2026, from -$16.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$11.1 million in Q1 2024 to a low of -$19.9 million in Q2 2023.
- A 5-year average of -$15.9 million and a median of -$16.0 million in 2025 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax slumped 134.03% in 2022 and jumped 42.44% in 2024, its largest moves.
- Tracing DSGN's Profit After Tax over 5 years: stood at -$17.3 million in 2022, then soared by 31.71% to -$11.8 million in 2023, then decreased by 15.28% to -$13.7 million in 2024, then dropped by 17.19% to -$16.0 million in 2025, then dropped by 10.25% to -$17.6 million in 2026.
- Business Quant data shows DSGN's Profit After Tax at -$17.6 million in Q1 2026, -$16.0 million in Q4 2025, and -$17.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -17.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.64 Mn |
| Dec 31, 2025 | -16.00 Mn |
| Sep 30, 2025 | -17.00 Mn |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -17.72 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -13.04 Mn |
| Jun 30, 2024 | -11.79 Mn |
| Mar 31, 2024 | -11.11 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Sep 30, 2023 | -15.79 Mn |
| Jun 30, 2023 | -19.94 Mn |
| Mar 31, 2023 | -19.29 Mn |
| Dec 31, 2022 | -17.34 Mn |
| Sep 30, 2022 | -19.25 Mn |
| Jun 30, 2022 | -15.99 Mn |
| Mar 31, 2022 | -13.27 Mn |
| Dec 31, 2021 | -11.47 Mn |
| Sep 30, 2021 | -11.32 Mn |
| Jun 30, 2021 | -7.64 Mn |